Bladder cancer: Novel molecular characteristics, diagnostic, and therapeutic implications

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 1, 2010, Pages 91-96

  Kompier, Lucie C ^a   van Tilborg, Angela A G ^a   Zwarthoff, Ellen C ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

Bladder cancer; FGFR3; Urine based surveillance

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 3; PROTEIN P53;

BLADDER CANCER; CANCER EPIDEMIOLOGY; CANCER GENETICS; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; GENE MUTATION; GENETIC RISK; HETEROZYGOSITY LOSS; HUMAN; MUSCLE METASTASIS; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

HUMANS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 3; URINARY BLADDER NEOPLASMS;

EID: 72549092697     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.06.007     Document Type: Review

References (29)

1. van Rhijn B.W., Vis A.N., van der Kwast T.H., et al. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol 21 (2003) 1912-1921
2. Knowles M.A. Molecular pathogenesis of bladder cancer. Int J Clin Oncol 13 (2008) 287-297
3. van Oers J.M., Zwarthoff E.C., Rehman I., et al. FGFR3 mutations indicate better survival in invasive upper urinary tract and bladder tumours. Eur Urol 55 (2009) 650-658
4. van Oers J.M., Lurkin I., van Exsel A.J., et al. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 11 (2005) 7743-7748
5. Bakkar A.A., Wallerand H., Radvanyi F., et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 63 (2003) 8108-8112
6. van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res 64 (2004) 1911-1914
7. Knowles M.A. Bladder cancer subtypes defined by genomic alterations. Scand J Urol Nephrol 218 Suppl (2008) 116-130
8. Jebar A.H., Hurst C.D., Tomlinson D.C., et al. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. Oncogene 24 (2005) 5218-5225
9. Lopez-Knowles E., Hernandez S., Malats N., et al. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors. Cancer Res 66 (2006) 7401-7404
10. Junker K., van Oers J.M., Zwarthoff E.C., et al. Fibroblast growth factor receptor 3 mutations in bladder tumors correlate with low frequency of chromosome alterations. Neoplasia 10 (2008) 1-7
11. Koed K., Wiuf C., Christensen L.L., et al. High-density single nucleotide polymorphism array defines novel stage and location-dependent allelic imbalances in human bladder tumors. Cancer Res 65 (2005) 34-45
12. Kiemeney L.A., Witjes J.A., Verbeek A.L., et al. The clinical epidemiology of superficial bladder cancer. Dutch South-East Cooperative Urological Group. Br J Cancer 67 (1993) 806-812
13. Kompier L.C., van der Aa M.N., Lurkin I., et al. The development of multiple bladder tumour recurrences in relation to the FGFR3 mutation status of the primary tumour. J Pathol 218 (2009) 104-112
14. van Oers J.M., Wild P.J., Burger M., et al. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours. Eur Urol 52 (2007) 760-768
15. Burger M., van der Aa M.N., van Oers J.M., et al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: A prospective study. Eur Urol 54 (2008) 835-844
16. Hernandez S., Lopez-Knowles E., Lloreta J., et al. Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas. J Clin Oncol 24 (2006) 3664-3671
17. van Rhijn B.W., van der Poel H.G., and van der Kwast T.H. Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 47 (2005) 736-748
18. Zwarthoff E.C. Detection of tumours of the urinary tract in voided urine. Scand J Urol Nephrol 218 Suppl (2008) 147-153
19. Van Tilborg A.A., Bangma C.H., and Zwarthoff E.C. Bladder cancer biomarkers and their role in surveillance and screening. Int J Urol 16 (2009) 23-30
20. van der Aa M.N., Zwarthoff E.C., Steyerberg E.W., et al. Microsatellite analysis of voided urine samples for surveillance of low-grade non-muscle-invasive urothelial carcinoma: Feasibility and clinical utility in a prospective multicenter study (cost-effectiveness of follow-up of urinary bladder cancer trial [CEFUB]). Eur Urol 55 (2008) 659-668
21. Vriesema J.L., Poucki M.H., Kiemeney L.A., et al. Patient opinion of urinary tests versus flexible urethrocystoscopy in follow-up examination for superficial bladder cancer: A utility analysis. Urology 56 (2000) 793-797
22. Yossepowitch O., Herr H.W., and Donat S.M. Use of urinary biomarkers for bladder cancer surveillance: Patient perspectives. J Urol 177 (2007) 1277-1282 Discussion 82
23. van der Aa M.N., Steyerberg E.W., Sen E.F., et al. Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: A randomized comparison. BJU Int 101 (2008) 1106-1110
24. Schrag D., Hsieh L.J., Rabbani F., et al. Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst 95 (2003) 588-597
25. Tomlinson D.C., Baldo O., Harnden P., et al. FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer. J Pathol 213 (2007) 91-98
26. Knowles M.A. Novel therapeutic targets in bladder cancer: Mutation and expression of FGF receptors. Future Oncol 4 (2008) 71-83
27. Tomlinson D.C., L'Hote C.G., Kennedy W., et al. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res 65 (2005) 10441-10449
28. Dyrskjot L., Thykjaer T., Kruhoffer M., et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat Genet 33 (2003) 90-96
29. Sanchez-Carbayo M., Socci N.D., Lozano J., et al. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol 24 (2006) 778-789